PTN
Palatin Technologies, Inc. AMEX Listed Oct 15, 1997$11.21
Mkt Cap $6.0M
52w Low $5.45
25.5% of range
52w High $28.00
50d MA $16.81
200d MA $15.63
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-0.0x
ROE
-193.0%
P/FCF
-0.3x
RSI (14)
25.40
ATR (14)
$0.92
Beta
0.94
50d MA
$16.81
200d MA
$15.63
Avg Volume
13.7K
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Cedar Brook Corporate Center · Cranbury, NJ 08512 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | AMC | -2.35 | -2.86 | -21.5% | 17.59 | -6.5% | +10.0% | +8.5% | +7.0% | +0.1% | +2.3% | — |
| Nov 14, 2025 | AMC | — | 4.26 | — | 10.80 | +0.0% | +17.9% | +6.5% | +1.8% | +5.0% | +57.5% | — |
| Sep 23, 2025 | AMC | -9.50 | -4.14 | +56.4% | 10.06 | +1.9% | +2.9% | -1.0% | -2.0% | -37.2% | +25.5% | — |
| May 21, 2025 | AMC | -0.17 | -0.53 | -211.8% | 6.00 | -8.3% | +0.0% | -8.3% | -9.1% | +0.0% | +0.0% | — |
| Feb 13, 2025 | AMC | -0.42 | -0.12 | +71.4% | 53.00 | -1.9% | -5.7% | +3.0% | -1.9% | +1.0% | -2.0% | — |
| Oct 1, 2024 | AMC | -0.55 | -0.51 | +7.3% | 44.00 | +1.1% | -6.8% | +1.2% | +6.0% | +3.4% | -4.4% | — |
| Sep 30, 2024 | AMC | -0.56 | -0.49 | +12.5% | 44.50 | +3.4% | -1.1% | -6.8% | +1.2% | +6.0% | +3.4% | — |
| May 15, 2024 | AMC | -0.66 | -0.53 | +19.7% | 103.50 | +1.4% | -1.4% | -2.0% | +2.0% | +1.5% | -1.4% | — |
| Feb 14, 2024 | AMC | -0.43 | -0.56 | -30.2% | 207.00 | -2.7% | -23.9% | -4.1% | +7.3% | -8.0% | +7.0% | — |
| Nov 14, 2023 | AMC | -0.75 | -0.48 | +36.0% | 96.00 | +1.0% | +3.6% | -3.0% | +1.6% | -0.5% | +3.1% | — |
| Sep 28, 2023 | AMC | -0.59 | -0.91 | -54.2% | 75.00 | -3.3% | +0.7% | +13.2% | +2.3% | -1.1% | +4.6% | — |
| May 16, 2023 | AMC | -0.59 | -0.63 | -6.8% | 129.00 | +0.8% | -5.4% | +0.4% | +2.4% | -1.6% | -0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.50 | $51.00 | +3.0% | +7.1% | -5.7% | +3.0% | -1.9% | +1.0% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.50 | $51.00 | +3.0% | +6.1% | -8.6% | +3.1% | +0.0% | +7.1% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.50 | $37.50 | +0.0% | +14.7% | +12.8% | +0.0% | +2.1% | +12.1% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.00 | $48.50 | +1.0% | +14.6% | -2.7% | +5.6% | +0.9% | +0.9% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $60.00 | $60.00 | +0.0% | -0.8% | -1.7% | -6.8% | +6.4% | +12.1% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.00 | $63.50 | +0.8% | -1.6% | -3.2% | -0.8% | -1.7% | -6.8% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.50 | $55.00 | +0.9% | +0.9% | -0.9% | +11.0% | -5.0% | +9.6% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $103.50 | $104.00 | +0.5% | -9.2% | +0.5% | -3.7% | -0.5% | +0.6% |
| Jun 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $92.50 | $95.00 | +2.7% | +6.5% | -1.5% | -6.2% | +0.0% | +13.7% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $120.50 | $110.50 | -8.3% | -14.1% | -1.4% | -2.0% | +2.0% | +1.5% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $104.00 | $104.00 | +0.0% | -1.4% | +14.6% | -2.6% | +6.1% | -0.8% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $93.50 | $95.50 | +2.1% | +9.6% | +2.9% | -5.2% | +4.0% | -1.4% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $198.50 | $110.00 | -44.6% | -38.3% | -18.0% | +9.5% | -10.0% | -0.5% |
| Feb 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $207.00 | $201.50 | -2.7% | -23.9% | -4.1% | +7.3% | -8.0% | +7.0% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $145.50 | $145.00 | -0.3% | -5.5% | +0.7% | +1.4% | -10.7% | -2.4% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $122.00 | $125.00 | +2.5% | +8.2% | +10.2% | -5.5% | +0.7% | +1.4% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $98.50 | $106.50 | +8.1% | +23.9% | +8.2% | +10.2% | -5.5% | +0.7% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $122.00 | $127.50 | +4.5% | +1.6% | -1.2% | -7.3% | +2.6% | +0.9% |
| Sep 9 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $315.50 | $300.00 | -4.9% | +7.4% | +15.0% | -3.2% | -12.6% | +2.0% |
| Sep 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $315.50 | $300.00 | -4.9% | +7.4% | +15.0% | -3.2% | -12.6% | +2.0% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $425.00 | $662.50 | +55.9% | +50.0% | +9.8% | +53.6% | -17.4% | -19.7% |
| Jun 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $1125.00 | $1762.50 | +56.7% | +11.1% | +15.0% | -1.7% | +0.9% | -5.3% |
No insider trades available.
Valuation
Market Cap
$6.0M
Enterprise Value
$3.5M
P/E (TTM)
—
Forward P/E
5.96x
PEG Ratio
-0.00x
P/B
—
P/S
0.47x
P/FCF
-0.28x
EV/EBITDA
—
Shares Out
538K
Financials (TTM)
Revenue
$12.9M
Net Income
-$6.2M
EBITDA
-$6.1M
Free Cash Flow
-$21.3M
Op Cash Flow
-$21.3M
EPS Basic
$-32.15
EPS Diluted
$-4.16
EPS Forward
$1.88
Gross Margin
99.8%
Op Margin
-50.6%
Net Margin
-48.5%
Balance Sheet
Total Assets
$3.3M
Total Liab.
$8.0M
Total Equity
-$4.8M
Cash
$2.6M
LT Debt
$0
Book Value/Sh
$-8.87
Debt/Equity
-0.03x
Current Ratio
0.36
Quick Ratio
0.36
Returns & Growth
ROE
-193.0%
ROA
-123.4%
ROIC
492.2%
Rev Growth YoY
-100.0%
EPS Growth YoY
-1491.6%
Price Returns
2W
-6.1%
1M
-30.6%
3M
-32.9%
6M
-28.2%
12M
+180.4%
Technicals
52W High
$28.00
52W Low
$5.45
50d MA
$16.81
200d MA
$15.63
RSI (14)
25.40
ATR (14)
$0.92
Beta
0.94
Avg Volume
14K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$55.00
High
$60.00
Low
$50.00
Median
$55.00
Data updated apr 26, 2026 9:10pm
· Source: financialmodelingprep.com